INTEGRA Dermal Regeneration Template, Integra Meshed Dermal Regeneration Template, and Integra Omnigraft Dermal Rege
Integra Lifesciences Corp. · Decision date Sep 18, 2026
What did the FDA decide?
The record for P900033/S117 describes a 30-Day Notice supplement to PMA P900033, filed by Integra Lifesciences Corp. for the wound and burn interactive dressing product code MGR. The stated purpose is installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The decision is OK30, dated 2026-09-18.
The source statement identifies only the WFI system scope; it does not name the manufacturing site, the equipment vendor, qualification protocols, or any effect on the finished device. As a supplement to an existing PMA, it is not a new approval of the whole device system, and the notice itself is not evidence of safety or clinical effectiveness. Specifics about the prior WFI system and what changed relative to it are absent from the supplied fields.
FDA approval order statement
installation and qualification of a new Water for Injection (WFI) pretreatment, generation, storage, and distribution system
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 18, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P900033/S117
- Regulatory pathway
- PMA supplement
- Applicant
- Integra Lifesciences Corp.
- Product code
- MGR
- Decision code
- OK30
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Dressing, wound and burn, interactive.
- Applicant
- Integra Lifesciences Corp.
- Product code
- MGR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P900033. Subsequent supplements may change the device or its indications.
FDA decision timeline
P900033 · Original PMA
INTEGRA DERMAL REGENERATION TEMPLATE
P900033/S117 received
Application receipt date recorded by FDA.
P900033/S117 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P900033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P900033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Integra Lifesciences Corp. | PMA approval | Mar 1, 1996 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Integra Lifesciences Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 105 Morgan Ln., Plainsboro, NJ, 08536
Sources and methodology
- Original FDA record: P900033/S117
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records